Comparative accuracy of cardiovascular risk prediction methods in primary care patients

OBJECTIVE To compare the relative accuracy of cardiovascular disease risk prediction methods based on equations derived from the Framingham heart study. DESIGN Risk factor data were collected prospectively from subjects being evaluated by their primary care physicians for prevention of cardiovascular disease. Projected cardiovascular risks were calculated for each patient with the Framingham equations, and also estimated from the risk tables and charts based on the same equations. SETTING 12 primary care practices (46 doctors) in Birmingham. PATIENTS 691 subjects aged 30–70 years. MAIN OUTCOME MEASURES Sensitivity, specificity, and positive and negative predictive values of the Framingham based risk tables and charts for treatment thresholds based on projected cardiovascular disease or coronary heart disease risk. RESULTS 59 subjects (8.5%) had projected 10 year coronary heart disease risks ⩾ 30%, and 291 (42.1%) had risks ⩾ 15%. At equivalent projected risk levels (10 year coronary heart disease ⩾ 30% and five year cardiovascular disease ⩾ 20%), the original Sheffield tables and those from New Zealand have the same sensitivities (40.0%, 95% confidence interval (CI) 26.6% to 57.8% v 41.2%, 95% CI 28.7% to 57.3%) and specificities (98.6%, 95% CI 97.2% to 99.3%v 99.7%, 95% CI 98.8% to 100%). Modifications to the Sheffield tables improve sensitivity (91.4%, 95% CI 81.3% to 96.9%) but reduce specificity (95.8%, 95% CI 93.9% to 97.3%). The revised joint British recommendations' charts have high specificity (98.7%, 95% CI 97.5% to 99.5%) and good sensitivity (84.7%, 95% CI 71.0% to 93.0%). CONCLUSIONS The revised joint British recommendations charts appear to have the best combination of sensitivity and specificity for use in primary care patients.

[1]  J. McCormack,et al.  Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  Tunstall-Pedoe "Absolute" is inappropriate for quantitative risk estimation , 2000, BMJ.

[3]  R. Jackson Guidelines on preventing cardiovascular disease in clinical practice , 2000, BMJ : British Medical Journal.

[4]  J. Norrie,et al.  Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods , 2000, BMJ : British Medical Journal.

[5]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[6]  L. Ramsay,et al.  Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.

[7]  L. Simons,et al.  Management of hyperlipidaemia. , 1987, Drug and therapeutics bulletin.

[8]  L. Ramsay,et al.  Lipid-lowering for prevention of coronary heart disease: what policy now? , 1996, Clinical science.

[9]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[10]  L. Poston,et al.  British Hypertension Society guidelines for hypertension management 1999: summary , 1999, BMJ.

[11]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[12]  Petros Nihoyannopoulos,et al.  Joint British recommendations on prevention of coronary heart disease in clinical practice , 1998, Heart.

[13]  Joint British recommendations on prevention of coronary heart disease in clinical practice: summary , 2001, BMJ : British Medical Journal.

[14]  I. U. Haq,et al.  Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population , 2000, BMJ : British Medical Journal.

[15]  D. Sackett,et al.  Guidelines for managing raised blood pressure , 1996, BMJ.

[16]  K. Pyörälä,et al.  Management of hyperlipidaemia. Why, when and how to treat. , 1997, European Heart Journal.

[17]  B. Swinburn 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. , 1996, The New Zealand medical journal.

[18]  Patrick Vallance,et al.  A simple computer program for guiding management of cardiovascular risk factors and prescribing , 1999, BMJ.

[19]  AF Jones Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines , 1997, The Lancet.

[20]  A. Jones,et al.  Laboratory‐based calculation of coronary heart disease risk in a hospital diabetic clinic , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[21]  D. Bhatnagar,et al.  Indications for cholesterol-lowering medication: comparison of risk-assessment methods , 1999, The Lancet.

[22]  J. French,et al.  Using the Framingham model to predict heart disease in the United Kingdom: retrospective study , 2000, BMJ : British Medical Journal.

[23]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.